Botanix Pharmaceuticals Limited (ASX:BOT)

Market Cap	52.00M -83.4%
Revenue (ttm)	33.80M +483.9%
Net Income	-69.77M
EPS	-0.03
Shares Out	2.74B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,433,884
Open	0.0190
Previous Close	0.0180
Day's Range	0.0170 - 0.0190
52-Week Range	0.0180 - 0.1700
Beta	0.86
Analysts	Strong Buy
Price Target	0.48 (+2,426.32%)
Est. Earnings	Nov 26, 2026

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 11
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BOT

Financial Performance

In fiscal year 2026, Botanix Pharmaceuticals's revenue was 33.80 million, an increase of 483.87% compared to the previous year's 5.79 million. Losses were -69.77 million, -19.25% less than in 2025.

Analyst Summary

According to 3 analysts, the average rating for BOT stock is "Strong Buy." The 12-month stock price target is $0.48, which is an increase of 2,426.32% from the latest price.

Price Target

$0.48

(2,426.32% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 1, 2026

Data Sources Report a data error